AstraZeneca’s $2 billion investment in Summit is designed not only to fund development but to operationalize combination testing for ivonescimab alongside AstraZeneca’s ADC pipeline. Clinical collaboration plans focus initially on ivonescimab paired with a CLDN18.2-directed ADC in gastrointestinal cancers, with the framework intended to scale across additional regimens. The combination concept reflects investor demand for clearer pathways to next-regimen oncology outcomes rather than single-agent differentiation. It also underscores the industrial push to integrate bispecific immune engagement with targeted cytotoxic delivery in the same trials. Across the sector, the decision adds to the momentum behind PD-1/VEGF bispecifics as core backbone assets for combination strategies.